M Stanley Cuts JD HEALTH TP to HKD45, Maintains Equalweight Rating
AASTOCKS News·
- Morgan Stanley updated its model for JD HEALTH and lowered its EPS forecasts for 2026 to 2028 by 1% to 9% while cutting the target price to HKD 45 with an Equalweight rating.
- The adjustments reflect slower nutritional supplement growth, reduced margin assumptions, intensifying e-commerce competition, and a slowdown in organic growth.
- Despite short-term margin pressures from upfront investments, the company is expected to benefit long-term from healthcare e-commerce expansion and parent company support.
